Lambert Assoumou

Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients

Claudine Duvivier, S. Kolta, Lambert Assoumou et al. · AIDS · 2009 · 236 citations

Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study

Jean‐Michel Molina, Jade Ghosn, Lambert Assoumou et al. · The Lancet HIV · 2022 · 134 citations

Sexual Health, Preventive Medicine, Treatment And Prevention +10

A Therapeutic Dendritic Cell-Based Vaccine for HIV-1 Infection

Felipe García, Núria Climent, Lambert Assoumou et al. · The Journal of Infectious Diseases · 2011 · 132 citations · Full text

Vaccination, Autologous Hiv-1, Plasma Viral Load +14

Doxycycline prophylaxis and meningococcal group B vaccine to prevent bacterial sexually transmitted infections in France (ANRS 174 DOXYVAC): a multicentre, open-label, randomised trial with a 2 × 2 factorial design

Jean‐Michel Molina, Béatrice Berçot, Lambert Assoumou et al. · The Lancet Infectious Diseases · 2024 · 129 citations

Vaccination, Vaccine Safety, Preventive Medicine +9

Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

José M. Gatell, Lambert Assoumou, Graeme Moyle et al. · AIDS · 2017 · 89 citations · Full text